Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies

NCT02193958 is registered in ClinicalTrials.gov with Fujifilm Pharmaceuticals U.S.A., Inc. as lead sponsor.

NCT NCT02193958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02193958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2014
Completion date
October 15, 2019
Enrollment
55 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aml, cmml, mds